Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANOPY-1: pembrolizumab + platinum chemotherapy ± canakinumab in first-line NSCLC
2024-511490-29-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of canakinumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Novartis. Primary endpoints: Incidence of dose limiting toxicities in the first 42 days of study treatment, Progression-free survival based on local investigator assessment as per RECIST 1.1 and 1 more. Started Jun 2024; status: completed.
02
Drugs
canakinumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-511490-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511490-29-00.